ARCT vs SMTI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.
SMTI exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 8.13. While the company maintains an impressive gross margin of 92.71%, this is offset by consistent net losses and a track record of massive earnings misses (average surprise of -587.40% over the last 4 quarters). There is a stark disconnect between the 'Strong Buy' analyst consensus and the underlying deterministic health metrics, which suggest high insolvency risk. The stock's long-term price trajectory is sharply negative, despite a recent short-term bounce.
Compare Another Pair
Related Comparisons
ARCT vs SMTI: Head-to-Head Comparison
This page compares Arcturus Therapeutics Holdings Inc. (ARCT) and Sanara MedTech Inc. (SMTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.